

Optimizing Anticoagulant Therapy in Atrial Fibrillation: A Comparative Analysis of Warfarin and Direct Oral Anticoagulants

Ge Zou*

School of Pharmacy, Shaanxi University of Chinese Medicine, China

Abstract

CE}cā&[æ~|æ}cāc@^tæ]^Āā•Ā]āç[çæ|Āā}Ā{æ}æ*ā}^Āæciāæ|Ā, āiā|æcā[]ĀçCEØDĀc[Ā]!^ç^}cĀ•c[\^Āæ}āĀ•^•c^ { ā&Ā^ { ā [Ā• { ĒĀV@ā•Ā æ!cā&|Ā!^•^}c•ĀæĀ& [{]æ!æciç^Āæ}æ|^•ā[-Ā, æt-æiā}Āæ}āĀāi^ĀcĀ [!æ|Āæ}cā&[æ*~|æ}c•ĀçŌUCEŌ•DĀ}Ā []cā { ā:ā } *Āæ}cā&[æ*~|æ}cĀ c@^tæ]^Ā-!^ĀçCEĀY@ā|Ā, æt-æiā}Ā@æ•Āā^}Āc@^Ācæ}āæ!āĀc@^tæ]^Ā-!^Āā^æāĀ•ĒĀŌUCEŌ•Ā [^Āæāçæ}cæ*^Ā•~&@Āæ•Ā]!^āā&cæā|Āā æ}cā&[æ*~|æ}cĀ^ Ā&c•ĒĀ^, ^ĀĀā!~*Āā}c^tæ&cā []•ĒĀæ}āĀ•ā []Ā, ^āĀā [•ā} *Ā!^*ā { ^ }•ĒĀŌ|ā}ā&æ|Āc!āæ|Ā@æçĀĀ•@ [, }Ā []Ēā}-Āiā [ĩac^Ā [Ā•~|^iā [ĩac^Ā [-Ā ŌUCEŌ•Ā [ç^!Ā, æt-æiā}Ā}Ā•c[\^Ā]!^ç^}cā []Ā, āc@ĀæĀ [[, ^ĀĀiā•\Ā [-Āā}c!æ&tæ}āæ|Ā@^ { [!@æ*^ĒĀP [, ^ç^ĒĀ & []•āā!æcā []•Ā•~&@Āæ•Ā& [•cĀæ}āĀ]æcĀ^}cĒ•]^Āā, &Ā-æ&c [!^Ā•@ [~|āĀ*~āĀĀc!^æc { ^ }cĀ•^|Ācā []ĒĀV@ā•Āæ}æ|^•ā•Āæā { •Āc [Āæ••ā•cĀ &|ā}ā&æ}•Ā}Ā { æ\ā} *Āā}- [! { ^āĀā^ā&ā&ā []•Āc [Āā {]! [ç^Ā [~c& [{ ^Āā}ĀçEØĀ { æ}æ*^ { ^ }cĒ

Study selection criteria

- Randomized controlled trials (RCTs), meta-analyses, systematic reviews, and observational studies comparing warfarin and DOACs in patients with atrial fibrillation were included.
 - Studies assessing efficacy, safety, convenience, cost-effectiveness, and patient-reported outcomes were considered.
 - Studies with relevant endpoints such as stroke, systemic embolism, major bleeding, intracranial hemorrhage, and mortality
-

Citation: Zou G (2024) Optimizing Anticoagulant Therapy in Atrial Fibrillation: A Comparative Analysis of Warfarin and Direct Oral Anticoagulants. World J Pharmacol Toxicol 7: 252.

be inherent biases in observational studies and meta-analyses that
